Extract notice to the Minister
Bimzelx (psoriasis) (nouvelle teneur)
Common name / Subject : bimekizumab
Name of the manufacturer : UCB
Form : Sol. Inj. S.C. (ser); Sol. Inj. S.C. (stylo)
Dosage : 160 mg/ml (2 ml)
Name of the manufacturer : UCB
Form : Sol. Inj. S.C. (ser); Sol. Inj. S.C. (stylo)
Dosage : 160 mg/ml (2 ml)
Indication : Psoriasis en plaques
INESSS' Recommendation
Inscription - Sous conditions
Minister's decisions
Surseoir à la décision (2025-04-10)
Evaluation published on April 02, 2025